Chair
Member
Chairman of the board
Financial expert
Audit Committee Position

Stuart Duty

Mr. Stuart Duty is an experienced financial executive with over 30 years in finance and investment banking building leading healthcare teams on multiple platforms with a history of substantial growth in both revenue and personnel. Mr. Duty has focused primarily on biotechnology and specialty pharmaceuticals clients for much of his career, advising senior executives and boards on a range of financing activities and strategic transactions. His advisory activities spanned a global client base including significant in-country and cross-border transactions in the US, Japan, China, Canada and many European countries. Mr. Duty was a Senior Managing Director at Guggenheim Securities, LLC from 2012 to 2023. Previously, he held senior roles at Piper Jaffray and Montgomery Securities. Mr. Duty also held operating roles at Oracle Partners as Chief Operating Officer and at Curative Technologies as Director, Business Development. He began his career at Kidder Peabody. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A from Harvard Business School.
Chair

Thomas King

Mr. Thomas King has served as an independent biotechnology consultant and advisor since August 2016. Mr. King served as a member of the board of directors of VIVUS, Inc., a publicly traded pharmaceutical company, from May 2017 to December 2020, serving as interim Chief Executive Officer from December 2017 to April 2018 and interim President from April 2018 to May 2018. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc. from June 2003 until it was acquired by Grupo Ferrer in August 2016. From October 2015 to August 2016, Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development stage company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation, including President and Chief Operating Officer from January 1995 to January 1997 and President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors from January 1995 until it was acquired by Cephalon, Inc., Mr. King currently serves on the board of directors of TFF Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company and Kinaset Therapeutics, Inc. and Concentric Analgesics, Inc., both privately-held biopharmaceutical companies. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.
Member

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Member

Thomas Sellig

Mr. Tom Sellig brings more than 30 years of global experience in the life sciences and pharmaceutical services industries. He is currently CEO of Adare Pharma Solutions, a global technology-driven Contract Development and Manufacturing Organization specializing in oral solid dosage forms. From 2019 to 2021 Tom served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Prior to LabConnect, Tom was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Earlier, Tom was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Early in his career, Tom had a variety of sales and marketing leadership roles at Procter & Gamble, American Home Products, and Ascent Pediatrics. Tom received his bachelor’s degree in Economics from Vanderbilt University and an MBA from New York University.
Member

Audit Committee Charter

Download
Compensation Committee Position

Thomas King

Mr. Thomas King has served as an independent biotechnology consultant and advisor since August 2016. Mr. King served as a member of the board of directors of VIVUS, Inc., a publicly traded pharmaceutical company, from May 2017 to December 2020, serving as interim Chief Executive Officer from December 2017 to April 2018 and interim President from April 2018 to May 2018. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc. from June 2003 until it was acquired by Grupo Ferrer in August 2016. From October 2015 to August 2016, Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development stage company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation, including President and Chief Operating Officer from January 1995 to January 1997 and President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors from January 1995 until it was acquired by Cephalon, Inc., Mr. King currently serves on the board of directors of TFF Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company and Kinaset Therapeutics, Inc. and Concentric Analgesics, Inc., both privately-held biopharmaceutical companies. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.
Chair

Vaughn B. Himes, Ph.D.

Vaughn B. Himes, Ph.D. served as Chief Technical Officer at Seagen, Inc. from August 2016 to December 2023. Dr. Himes joined Seagen as Executive Vice President, Technical Operations in April 2009 and served as Executive Vice President, Technical Operations and Process Science from July 2012 until August 2016. Previously, Dr. Himes was with ZymoGenetics, Inc. from November 2005 to March 2009, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. From March 2003 to October 2005, he was Vice President, Manufacturing at Corixa, Inc. Prior to that, he held Vice President positions in manufacturing and development at Targeted Genetics and Genovo, Inc. Dr. Himes received a B.A. in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.
Member

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Chair

Stuart Duty

Mr. Stuart Duty is an experienced financial executive with over 30 years in finance and investment banking building leading healthcare teams on multiple platforms with a history of substantial growth in both revenue and personnel. Mr. Duty has focused primarily on biotechnology and specialty pharmaceuticals clients for much of his career, advising senior executives and boards on a range of financing activities and strategic transactions. His advisory activities spanned a global client base including significant in-country and cross-border transactions in the US, Japan, China, Canada and many European countries. Mr. Duty was a Senior Managing Director at Guggenheim Securities, LLC from 2012 to 2023. Previously, he held senior roles at Piper Jaffray and Montgomery Securities. Mr. Duty also held operating roles at Oracle Partners as Chief Operating Officer and at Curative Technologies as Director, Business Development. He began his career at Kidder Peabody. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A from Harvard Business School.
Member

Thomas King

Mr. Thomas King has served as an independent biotechnology consultant and advisor since August 2016. Mr. King served as a member of the board of directors of VIVUS, Inc., a publicly traded pharmaceutical company, from May 2017 to December 2020, serving as interim Chief Executive Officer from December 2017 to April 2018 and interim President from April 2018 to May 2018. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc. from June 2003 until it was acquired by Grupo Ferrer in August 2016. From October 2015 to August 2016, Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development stage company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation, including President and Chief Operating Officer from January 1995 to January 1997 and President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors from January 1995 until it was acquired by Cephalon, Inc., Mr. King currently serves on the board of directors of TFF Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company and Kinaset Therapeutics, Inc. and Concentric Analgesics, Inc., both privately-held biopharmaceutical companies. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.
Member

Nominating and Corporate Governance Committee Charter

Download
CMC Committee Position

Vaughn B. Himes, Ph.D.

Vaughn B. Himes, Ph.D. served as Chief Technical Officer at Seagen, Inc. from August 2016 to December 2023. Dr. Himes joined Seagen as Executive Vice President, Technical Operations in April 2009 and served as Executive Vice President, Technical Operations and Process Science from July 2012 until August 2016. Previously, Dr. Himes was with ZymoGenetics, Inc. from November 2005 to March 2009, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. From March 2003 to October 2005, he was Vice President, Manufacturing at Corixa, Inc. Prior to that, he held Vice President positions in manufacturing and development at Targeted Genetics and Genovo, Inc. Dr. Himes received a B.A. in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.
Chair

Thomas Sellig

Mr. Tom Sellig brings more than 30 years of global experience in the life sciences and pharmaceutical services industries. He is currently CEO of Adare Pharma Solutions, a global technology-driven Contract Development and Manufacturing Organization specializing in oral solid dosage forms. From 2019 to 2021 Tom served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Prior to LabConnect, Tom was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Earlier, Tom was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Early in his career, Tom had a variety of sales and marketing leadership roles at Procter & Gamble, American Home Products, and Ascent Pediatrics. Tom received his bachelor’s degree in Economics from Vanderbilt University and an MBA from New York University.
Member

CMC Committee Charter

Download

Stuart Duty

Mr. Stuart Duty is an experienced financial executive with over 30 years in finance and investment banking building leading healthcare teams on multiple platforms with a history of substantial growth in both revenue and personnel. Mr. Duty has focused primarily on biotechnology and specialty pharmaceuticals clients for much of his career, advising senior executives and boards on a range of financing activities and strategic transactions. His advisory activities spanned a global client base including significant in-country and cross-border transactions in the US, Japan, China, Canada and many European countries. Mr. Duty was a Senior Managing Director at Guggenheim Securities, LLC from 2012 to 2023. Previously, he held senior roles at Piper Jaffray and Montgomery Securities. Mr. Duty also held operating roles at Oracle Partners as Chief Operating Officer and at Curative Technologies as Director, Business Development. He began his career at Kidder Peabody. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A from Harvard Business School.

Thomas King

Mr. Thomas King has served as an independent biotechnology consultant and advisor since August 2016. Mr. King served as a member of the board of directors of VIVUS, Inc., a publicly traded pharmaceutical company, from May 2017 to December 2020, serving as interim Chief Executive Officer from December 2017 to April 2018 and interim President from April 2018 to May 2018. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc. from June 2003 until it was acquired by Grupo Ferrer in August 2016. From October 2015 to August 2016, Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development stage company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation, including President and Chief Operating Officer from January 1995 to January 1997 and President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors from January 1995 until it was acquired by Cephalon, Inc., Mr. King currently serves on the board of directors of TFF Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company and Kinaset Therapeutics, Inc. and Concentric Analgesics, Inc., both privately-held biopharmaceutical companies. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Thomas Sellig

Mr. Tom Sellig brings more than 30 years of global experience in the life sciences and pharmaceutical services industries. He is currently CEO of Adare Pharma Solutions, a global technology-driven Contract Development and Manufacturing Organization specializing in oral solid dosage forms. From 2019 to 2021 Tom served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Prior to LabConnect, Tom was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Earlier, Tom was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Early in his career, Tom had a variety of sales and marketing leadership roles at Procter & Gamble, American Home Products, and Ascent Pediatrics. Tom received his bachelor’s degree in Economics from Vanderbilt University and an MBA from New York University.

Thomas King

Mr. Thomas King has served as an independent biotechnology consultant and advisor since August 2016. Mr. King served as a member of the board of directors of VIVUS, Inc., a publicly traded pharmaceutical company, from May 2017 to December 2020, serving as interim Chief Executive Officer from December 2017 to April 2018 and interim President from April 2018 to May 2018. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc. from June 2003 until it was acquired by Grupo Ferrer in August 2016. From October 2015 to August 2016, Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development stage company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation, including President and Chief Operating Officer from January 1995 to January 1997 and President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors from January 1995 until it was acquired by Cephalon, Inc., Mr. King currently serves on the board of directors of TFF Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company and Kinaset Therapeutics, Inc. and Concentric Analgesics, Inc., both privately-held biopharmaceutical companies. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.

Vaughn B. Himes, Ph.D.

Vaughn B. Himes, Ph.D. served as Chief Technical Officer at Seagen, Inc. from August 2016 to December 2023. Dr. Himes joined Seagen as Executive Vice President, Technical Operations in April 2009 and served as Executive Vice President, Technical Operations and Process Science from July 2012 until August 2016. Previously, Dr. Himes was with ZymoGenetics, Inc. from November 2005 to March 2009, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. From March 2003 to October 2005, he was Vice President, Manufacturing at Corixa, Inc. Prior to that, he held Vice President positions in manufacturing and development at Targeted Genetics and Genovo, Inc. Dr. Himes received a B.A. in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Bridget Martell, M.A., M.D.

Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.

Stuart Duty

Mr. Stuart Duty is an experienced financial executive with over 30 years in finance and investment banking building leading healthcare teams on multiple platforms with a history of substantial growth in both revenue and personnel. Mr. Duty has focused primarily on biotechnology and specialty pharmaceuticals clients for much of his career, advising senior executives and boards on a range of financing activities and strategic transactions. His advisory activities spanned a global client base including significant in-country and cross-border transactions in the US, Japan, China, Canada and many European countries. Mr. Duty was a Senior Managing Director at Guggenheim Securities, LLC from 2012 to 2023. Previously, he held senior roles at Piper Jaffray and Montgomery Securities. Mr. Duty also held operating roles at Oracle Partners as Chief Operating Officer and at Curative Technologies as Director, Business Development. He began his career at Kidder Peabody. Mr. Duty holds a B.A. in Biochemistry from Occidental College and an M.B.A from Harvard Business School.

Thomas King

Mr. Thomas King has served as an independent biotechnology consultant and advisor since August 2016. Mr. King served as a member of the board of directors of VIVUS, Inc., a publicly traded pharmaceutical company, from May 2017 to December 2020, serving as interim Chief Executive Officer from December 2017 to April 2018 and interim President from April 2018 to May 2018. Previously, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Alexza Pharmaceuticals, Inc. from June 2003 until it was acquired by Grupo Ferrer in August 2016. From October 2015 to August 2016, Mr. King also served as Chief Financial Officer and Chief Accounting Officer of Alexza Pharmaceuticals, Inc. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development stage company. From January 1994 to February 2001, Mr. King held various senior executive positions at Anesta Corporation, including President and Chief Operating Officer from January 1995 to January 1997 and President and Chief Executive Officer from January 1997 to October 2000, and was a member of the board of directors from January 1995 until it was acquired by Cephalon, Inc., Mr. King currently serves on the board of directors of TFF Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company and Kinaset Therapeutics, Inc. and Concentric Analgesics, Inc., both privately-held biopharmaceutical companies. Mr. King received a B.A. in chemistry from McPherson College and an M.B.A. from the University of Kansas Graduate School of Business.

Vaughn B. Himes, Ph.D.

Vaughn B. Himes, Ph.D. served as Chief Technical Officer at Seagen, Inc. from August 2016 to December 2023. Dr. Himes joined Seagen as Executive Vice President, Technical Operations in April 2009 and served as Executive Vice President, Technical Operations and Process Science from July 2012 until August 2016. Previously, Dr. Himes was with ZymoGenetics, Inc. from November 2005 to March 2009, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. From March 2003 to October 2005, he was Vice President, Manufacturing at Corixa, Inc. Prior to that, he held Vice President positions in manufacturing and development at Targeted Genetics and Genovo, Inc. Dr. Himes received a B.A. in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.

Thomas Sellig

Mr. Tom Sellig brings more than 30 years of global experience in the life sciences and pharmaceutical services industries. He is currently CEO of Adare Pharma Solutions, a global technology-driven Contract Development and Manufacturing Organization specializing in oral solid dosage forms. From 2019 to 2021 Tom served as Chief Executive Officer of LabConnect, a clinical trial laboratory services organization. Prior to LabConnect, Tom was Chief Commercial Officer at ConnectiveRx, where he was responsible for all commercial and customer-facing activity at the patient support and patient access company. Earlier, Tom was Senior Vice President of Global Sales at Patheon, where he played an integral role in the company’s sale to and integration with Thermo Fisher. Previously, he served as the Global Vice President of Sales and Client Services at Covance. Early in his career, Tom had a variety of sales and marketing leadership roles at Procter & Gamble, American Home Products, and Ascent Pediatrics. Tom received his bachelor’s degree in Economics from Vanderbilt University and an MBA from New York University.